Physician profile
David Crownover
NPI 1376654566
$9,356.33
in general payments reported to CMS, 2019-2025
21 companies · $497 in 2025
The $497 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.73 · 2020: $14.06 · 2021: $3,444 · 2022: $1,527 · 2023: $287 · 2024: $3,501 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,750 · Food and Beverage: $1,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,750.00 |
| Food and Beverage | $1,534.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $5,753.21 | 2021-2024 | Nexplanon |
| Merck Sharp & Dohme LLC | $1,788.22 | 2020-2024 | M-M-R II, Gardasil 9, Gardasil |
| Intuitive Surgical, INC. | $611.29 | 2019-2025 | Da Vinci Surgical System |
| Pfizer INC. | $401.57 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $173.93 | 2023-2025 | Myfembree |
| Abbvie INC. | $128.87 | 2021-2024 | |
| Astellas Pharma US INC | $99.02 | 2025 | Veozah |
| Sage Therapeutics, LLC | $61.33 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.54 | 2022-2023 | |
| Coopersurgical, INC. | $48.71 | 2019 | |
| Davol INC. | $35.75 | 2024 | |
| Myovant Sciences INC. | $32.15 | 2021 | |
| Gilead Sciences, INC. | $30.87 | 2025 | |
| Exeltis, USA INC. | $22.45 | 2024 | Slynd |
| Shield Therapeutics INC | $19.35 | 2023 | Accrufer |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $18.25 | 2019 | |
| Lilly USA, LLC | $18.16 | 2025 | Mounjaro, Zepbound |
| Cranial Technologies, INC | $17.52 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.91 | 2023 | Gvoke Hypopen |
| Becton, Dickinson and Company | $14.03 | 2025 | Arista |
| Hologic Sales and Service, LLC | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Crownover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.